Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2471 to 2480 of 2586 total matches.

Cancer Screening

   
Treatment Guidelines from The Medical Letter • Dec 01, 2012  (Issue 124)
for women 40-49 years old. Med Lett Drugs Ther 2009; 51:97. 3. N Shen et al. Mammography in 40-year-old ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec;10(124):87-94 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

A Vaccine for Rotavirus

   
The Medical Letter on Drugs and Therapeutics • May 21, 1999  (Issue 1053)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The FDA has approved the marketing of RotaShield, a live oral vaccine for prevention of infantile rotavirus infection. Rotaviruses are segmented double-stranded RNA viruses that are the most common cause of severe diarrhea and dehydration in infants and young children.
Med Lett Drugs Ther. 1999 May 21;41(1053):50 |  Show IntroductionHide Introduction

Screening for Melanoma

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011  (Issue 1372)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter® On Drugs ...
In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):72 |  Show IntroductionHide Introduction

An Imaging Agent for Amyloid

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1394) July 9, 2012 ...
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5 |  Show IntroductionHide Introduction

In Brief: Meningococcal Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013  (Issue 1429)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1429) November 11, 2013 ...
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo, a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old.SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C,...
Med Lett Drugs Ther. 2013 Nov 11;55(1429):92 |  Show IntroductionHide Introduction

In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
.6 1. In brief: Johnson & Johnson COVID-19 vaccine suspended. Med Lett Drugs Ther 2021 May 3 (epub ...
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the...
Med Lett Drugs Ther. 2021 May 17;63(1624):e1 |  Show IntroductionHide Introduction

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
vision loss. Antithrombotic drugs should be stopped temporarily before implantation of Encelto ...
Revakinagene taroretcel-lwey (Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It is the first treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e74   doi:10.58347/tml.2025.1727f |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

The Viralizer For The Common Cold

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Med Lett Drugs Ther. 1989 Jan 27;31(784):8 |  Show IntroductionHide Introduction